To emphasize a further distinction between patient population for BETonMACE/RVX-208 and EMPG-REG OUTCOME/Jardiance, here is another post and the relevant part pasted below:

"#4: Patient ACS history: This may be the most important one. BETonMACE will require patients to have had an acute coronary syndrome event within 7-90 days of randomization in the trial. ASSURE/SUSTAIN did not have this requirement. How significant is this? Re-watch the 9/25 corporate update presentation during Kausik Ray's and Michael Sweeney's part and they discuss the importance of this. Also, at around the 1 hour 30 min mark of the Q&A Kausik addresses a question related to this. Both the EXAMINE and EMPA-REG OUTCOME trials were based on diabetic patients using 3-point MACE. Only EXAMINE required an ACS event w/i 90 days of randomization. Examine had a 3-point MACE event rate of about 10.5% at 18 months (about the same for treatment and placebo groups). The event rate of EMPA-REG OUTCOME was more modest at around 6% at 18 months (as best asI can extrapolate from the graph). So long story short, diabetic pateints in BETonMACE trial will be at a much higher risk for a 3-point MACE event than those diabetic patients in ASSURE/SUSTAIN because of this very recent ACS inclusion event."